Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 8/20 | 0.41 |
| ▸ | JAK2 | O60674 | 7/20 | 0.41 |
| ▸ | JAK1 | P23458 | 6/20 | 0.41 |
| ▸ | TYK2 | P29597 | 3/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | MERTK | Q12866 | 1/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.38 |
| ▸ | FLT4 | P35916 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24852530 | 0.89 | IGF1R (0.46) | JAK3JAK2JAK1TYK2IGF1R | |
| SCHEMBL30754127 | 0.87 | JAK3 (0.39) | JAK3JAK2JAK1TYK2IGF1R | |
| SCHEMBL30754120 | 0.87 | JAK2 (0.43) | JAK3JAK2JAK1TYK2FLT3 | |
| SCHEMBL24852475 | 0.87 | JAK2 (0.43) | JAK3JAK2JAK1TYK2FLT3 | |
| SCHEMBL27058973 | 0.87 | JAK3 (0.39) | JAK3JAK2JAK1TYK2IGF1R | |
| SCHEMBL26970754 | 0.87 | JAK2 (0.43) | JAK3JAK2JAK1TYK2FLT3 | |
| SCHEMBL30754131 | 0.86 | DDR2 (0.41) | JAK3JAK2JAK1TYK2 | |
| SCHEMBL24852520 | 0.86 | DDR2 (0.41) | JAK3JAK2JAK1TYK2 | |
| SCHEMBL24852472 | 0.85 | JAK2 (0.41) | JAK3JAK2JAK1TYK2FLT3 | |
| SCHEMBL24853381 | 0.85 | IGF1R (0.44) | JAK3JAK2JAK1TYK2IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030870-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030870-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | JAK2, JAK1, JAK3 | JAK3 3/4885JAK2 1/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.